Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

Structure Therapeutics (GPCR) announced two poster presentations on aleniglipron at ObesityWeek, scheduled for November 15, 2026, in National Harbor, Maryland.

Rhea-AI Summary

Structure Therapeutics (GPCR) announced two poster presentations on aleniglipron at ObesityWeek, scheduled for November 15, 2026, in National Harbor, Maryland.

The posters cover the ACCESS trial open-label extension in participants with overweight or obesity and dose-ranging effects in the ACCESS trials. Both presentations run from 2:30–3:30 p.m. ET in Exhibit Hall BCD.

Key Terms

open-label extension, glp-1ra, dose-ranging

3 terms

open-label extension medical

"Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

glp-1ra medical

"Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity"

A GLP-1 receptor agonist (GLP-1RA) is a class of medications that mimic a natural gut hormone to help lower blood sugar, slow stomach emptying and curb appetite — like a thermostat that helps regulate blood sugar and hunger. They matter to investors because they are used to treat diabetes and obesity, can generate large, sustained drug sales, shift healthcare spending and pricing, and drive regulatory and competitive dynamics that affect pharmaceutical company valuations.

dose-ranging medical

"Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity"

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD.

Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension
Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET
Location: Exhibit Hall BCD

Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials
Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET
Location: Exhibit Hall BCD

About Aleniglipron
Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Jen Robinson
Structure Therapeutics Inc.
Jennifer.Robinson@structuretx.com

Media:
Dan Budwick
1AB
Dan@1abmedia.com